Scinovex
articleTop 10% cited

Low rectal cancer

Diseases of the Colon & Rectum · 1998 · Vol. 41(9) · pp. 1087–1096
Angelita Habr‐GamaPedro Marcos Santinho Bueno de SouzaUlysses RibeiroWladimir NadalinRene Claúdio GanslAfonso Henrique Silva e SousaFábio Guilherme CamposJoaquim Gama‐Rodrigues

Abstract

Combined up-front chemoradiotherapy was associated with tolerable and acceptable side effects. A significant number of patients had complete disappearance of their tumors (30.5 percent) within a median follow-up of 36 months. This regimen spared 26.2 percent of patients from surgical treatment and allowed sphincter-saving management in 38.1 percent of patients who may have required abdominoperineal resection. Preliminary results of this trial suggests a reduction in the number of local recurrences and reinforces the concept that infiltrative low rectal cancer may be initially treated by chemoradiotherapy.

Colorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasGastric Cancer Management and OutcomesMedicineRegimenRadiation therapySurgeryBiopsyChemotherapyColoanal anastomosisFluorouracilColorectal cancerRadiology

MeSH terms

AdenocarcinomaAdultAgedAged, 80 and overAnastomosis, SurgicalAntineoplastic Combined Chemotherapy ProtocolsLeucovorinCombined Modality TherapyFemaleFluorouracilFollow-Up StudiesHumansMaleMiddle AgedProspective Studies
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.